FRC-222

FRC-222 (Compound 2n) binds to purified recombinant CHD1 tandem chromodomain with a K_d of 0.15 μM^[1].
FRC-222 inhibits the interaction between purified recombinant CHD1 tandem chromodomain and H3K4me3 peptide with an IC₅₀ of 0.49 μM^[1].
FRC-222 (25-100 μM) engages endogenous full-length CHD1 in HEK293T cell lysate, competitively inhibiting its binding to LSD1-K114me3 peptide in a concentration-dependent manner^[1].
FRC-222 (10 μM) shows high selectivity against purified LSD1, KMT9, METTL21A, EHMT2 (G9a), SET8, and NSD2 enzymes, with minimal inhibition of DNMT1^[1].
FRC-222 (16 μM) shows high selectivity against purified TAF3, SPIN1, and PHF8 methyl-lysine reader domains, with no significant inhibition of H3K4me3 peptide binding^[1].
FRC-222 (0.8-6 μM; 48 h) impairs the viability of PC-3M-Luc prostate cancer cells in a concentration-dependent manner, with significant inhibition observed at concentrations ≥1.8 μM^[1].
FRC-222 (0.8-6 μM; 48 h) potently impairs the viability of 22Rv1 prostate cancer cells in a concentration-dependent manner, with significant inhibition observed at concentrations ≥1.8 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.